GRAL
GRAIL, Inc.
NASDAQ · USHealthcareMedical - Diagnostics & Research
$68.91-5.11%
Price as of Jul 20, 2026
GRAL growth
GRAIL, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- +19.4%
- EBITDA
- +36.3%
- EBIT
- +74.3%
- EPS
- +83.0%
- Free cash flow
- +37.7%
- Operating cash flow
- +37.4%
Forward estimates
- Revenue
- +25.8%
- EBITDA
- +41.8%
- EPS
- -4.8%
Three-year CAGR
- Revenue
- +38.4%
- EBITDA
- +38.0%
- EBIT
- +75.6%
- Net income
- +79.9%
- EPS
- +82.5%
- Free cash flow
- +48.7%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.